JAMA Cardiology July 2026 Finerenone and Blood Pressure in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

This study investigates how the medication finerenone affects patients suffering from heart failure with mildly reduced or preserved ejection fraction, specifically focusing on its impact on blood pressure. The researchers discovered that while the drug consistently lowered systolic blood pressure, these cardiovascular improvements—including fewer hospitalizations and lower mortality rates—occurred regardless of a patient's initial blood pressure levels. Crucially, the data suggests that the drug's protective benefits are independent of its blood-pressure-lowering effects, meaning it helps the heart through mechanisms beyond just reducing hypertension. Ultimately, the trial confirms that finerenone is both safe and effective for a wide range of patients, regardless of whether their blood pressure was high or low at the start of treatment.